Clinical Trials Browser

Terminated × Triple Negative Breast Neoplasms × Doxorubicin × Clear all

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2 Terminated

8 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02833766 2021-09-29

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

Phase 2 Terminated

48 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms